Curis Inc
NASDAQ:CRIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Wah Wo Holdings Group Ltd
HKEX:9938
|
HK |
|
K2A Knaust & Andersson Fastigheter AB (publ)
STO:K2A PREF
|
SE |
|
GMR Airports Infrastructure Ltd
BSE:532754
|
IN |
|
S
|
SkyWorld Development Bhd
KLSE:SKYWLD
|
MY |
|
Guangzhou Tech-Long Packaging Machinery Co Ltd
SZSE:002209
|
CN |
|
S
|
Sundiro Holding Co Ltd
SZSE:000571
|
CN |
|
SIASUN Robot & Automation Co Ltd
SZSE:300024
|
CN |
Curis Inc
Total Equity
Curis Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Curis Inc
NASDAQ:CRIS
|
Total Equity
$5.5m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Curis Inc
Glance View
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
See Also
What is Curis Inc's Total Equity?
Total Equity
5.5m
USD
Based on the financial report for Dec 31, 2025, Curis Inc's Total Equity amounts to 5.5m USD.
What is Curis Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-22%
The average annual Total Equity growth rates for Curis Inc have been -51% over the past three years , -47% over the past five years , and -22% over the past ten years .
